MISSION

The Flare audits unpublished, shelved, withdrawn, and terminated clinical trial data in the autoimmune sector. We translate raw data into transparent briefings for patients, families, advocacy groups, and independent researchers.

Two of the most serious complications of lupus are also two of the most under-discussed: neuropsychiatric involvement and kidney disease. This briefing audits both. Neuropsychiatric lupus (NPSLE) can produce cognitive decline, mood disorders, and neuropathy while standard blood panels remain entirely normal because the damage is happening inside the central nervous system, not in the bloodstream where routine labs look. Lupus nephritis, which affects up to half of all SLE patients, is classified through a kidney biopsy system that most patients never see explained. Neither condition has a dedicated FDA-approved treatment. Both have active trial records worth knowing.

Neuropsychiatric lupus is defined across 19 separate syndromes by the American College of Rheumatology, spanning everything from seizures and psychosis to cognitive dysfunction, mood disorders, and peripheral neuropathy. Published research estimates that between 17 and 75 percent of people with SLE develop some form of neuropsychiatric involvement during the course of their disease. That wide range reflects a fundamental problem: NPSLE is difficult to diagnose, and the standard tools most physicians use are not designed to find it.

The central issue is that lupus activity inside the brain does not always show up in blood work. In active SLE, autoantibodies can cross a compromised blood-brain barrier — the protective membrane separating the bloodstream from the central nervous system — and act directly on brain tissue. That process does not reliably generate the elevated antibody levels or inflammatory markers that standard labs are built to detect. A patient can have normal dsDNA, normal complement, normal CRP, and a normal MRI, while active immune-mediated damage is occurring in the CNS. Published case records document exactly this pattern: patients presenting with psychosis or significant cognitive decline whose routine workups were unremarkable, but whose specialized neuroimaging showed perfusion abnormalities consistent with NPSLE.

The damage also extends beyond the brain. A post-hoc analysis of five Phase 3 belimumab trials found that NPSLE patients were nearly three times more likely to accumulate organ damage overall compared to SLE patients without neuropsychiatric involvement — and that association extended beyond the nervous system to the cardiovascular, musculoskeletal, and skin domains. Neuropsychiatric lupus is not an isolated complication. It accelerates damage across the body.

The ACR's 19-syndrome classification is the standard framework, but it has a documented limitation that matters practically for patients: it does not include small fiber neuropathy. This is the same painful, burning neuropathy that readers of the Sjögren's briefings will recognize — and it is documented in SLE patients as well. Published data shows that 17 percent of SLE patients with lupus-attributable peripheral neuropathy have small fiber neuropathy specifically, with skin biopsy findings showing nerve fiber loss at the level of the dorsal root ganglion. That is a structural finding, not a functional one — and it will not appear on a standard nerve conduction study, because those tests only detect large fiber neuropathy.

If you have been told your nerve conduction study was normal and your symptoms are being attributed to anxiety or fibromyalgia, the clinical record supports asking specifically whether a skin punch biopsy for intraepidermal nerve fiber density has been considered. It is the same test documented in the Sjögren's peripheral neuropathy guidelines published in late 2025, and the diagnostic gap is identical.

There are currently no FDA-approved treatments specifically for NPSLE. Treatment follows the type of event: anticoagulation for thrombotic events, immunosuppression for inflammatory presentations, and symptom management for cognitive and mood manifestations. Published reviews describe the controlled clinical trial record for NPSLE management as sparse, with therapeutic guidance derived primarily from observational cohort data rather than randomized trials.

What the pipeline does show is indirect coverage. Most of the large Phase 3 SLE trials — the BLISS series for belimumab, the TULIP series for anifrolumab, and others — enrolled broad SLE populations that included patients with neuropsychiatric involvement. Post-hoc analyses of those datasets have produced useful data: the belimumab trial analysis cited above documented NPSLE's impact on damage accrual across organ systems. But these are secondary analyses of trials not designed to specifically evaluate NPSLE. A 2025 review in Current Opinion in Rheumatology identified three emerging therapeutic approaches for NPSLE: modulation of B-cell activity and autoantibodies through CAR-T and BTK inhibitors, reduction of systemic inflammation through JAK, TYK2, and anti-interferon agents, and direct neuroprotection through ACE inhibitors and ARBs — while noting that clinical trials specifically inclusive of NPSLE patients remain a priority unmet need.

Why no NPSLE-specific trials? The short answer is attribution. Determining that a neurological symptom is directly caused by lupus — rather than by a medication side effect, infection, antiphospholipid antibody syndrome, or another concurrent condition — is genuinely difficult and requires specialized evaluation. That complexity has historically made trial enrollment criteria for NPSLE-specific studies hard to standardize, which is why NPSLE coverage in the trial record tends to come through post-hoc analyses of broader SLE trials rather than dedicated studies. Several research groups have called this out explicitly as a gap the field needs to address.

Kidney involvement in SLE is common. Published estimates range from 40 to 60 percent of SLE patients developing lupus nephritis during their disease course, with higher rates in patients of African, Hispanic, and Asian descent. It is the leading driver of long-term organ damage and one of the primary contributors to mortality in SLE. Unlike neuropsychiatric lupus, kidney involvement does produce detectable signals in routine labs — protein in the urine, changes in kidney filtration rate, blood in the urine. But those signals alone do not tell a clinician what is actually happening inside the kidney.

That is what the biopsy is for. The International Society of Nephrology and the Renal Pathology Society established a classification system, the ISN/RPS classification, that categorizes lupus nephritis into six classes based on what is found in a kidney tissue sample. Understanding what class you have is not a technicality. It directly determines what treatment you receive.

A kidney biopsy in SLE patients does more than confirm lupus nephritis, it also identifies other kidney conditions that may coexist with or occur independently of LN, which can significantly change treatment decisions. Biopsy is not simply a confirmation step. It is a routing decision.

Two drugs are now approved specifically for lupus nephritis in adults: belimumab (2020) and voclosporin (2021). Both are used in combination with the standard background regimen of mycophenolate mofetil and low-dose steroids. Obinutuzumab (Gazyva) received FDA approval for active lupus nephritis in late 2025. In April 2026, the FDA accepted Genentech's supplemental application to expand that approval to broader SLE based on the ALLEGORY trial. A decision on the broader SLE indication is expected December 2026.

VOCAL Trial (NCT05288855) — Terminated. Aurinia Pharmaceuticals terminated the primary VOCAL study in February 2026, following the same DSMB recommendation that halted the VOCAL-EXT extension study in July 2025. Both the 24-week primary trial and its long-term extension are now terminated. The reason for the DSMB recommendation is not further detailed in publicly available records as of this briefing. Voclosporin remains approved for adults with active lupus nephritis; the pediatric indication remains unstudied in a completed controlled trial.

Proteinuria: The Kidney Signal Most Patients Recognize Last

Protein in the urine (proteinuria) is often the first laboratory sign of lupus nephritis, and it frequently develops before a patient notices any symptoms. The kidneys are designed to filter waste while retaining protein; when the filtering system is damaged by immune complex deposition, protein leaks through. A urine protein-to-creatinine ratio (UPCR) above 0.5 is generally the threshold that triggers further evaluation for lupus nephritis. Complete renal response in clinical trials is defined in part as getting that ratio back below 0.5. This is one of the most commonly used endpoints in lupus nephritis trial design. Which means when you see a trial reporting "complete renal response," it is using this measurement as one of its primary benchmarks.

Event 1

Event 2

Disclaimer: The Flare is an independent investigative journalism outlet. We are not medical providers, clinical trial sites, or financial advisors. This information is for educational and journalistic purposes only and does not constitute medical advice.